| Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or … JD Bradley, R Paulus, R Komaki, G Masters, G Blumenschein, S Schild, ... The lancet oncology 16 (2), 187-199, 2015 | 2054 | 2015 |
| A large-scale study of the ultrawideband microwave dielectric properties of normal, benign and malignant breast tissues obtained from cancer surgeries M Lazebnik, D Popovic, L McCartney, CB Watkins, MJ Lindstrom, J Harter, ... Physics in medicine & biology 52 (20), 6093, 2007 | 1481 | 2007 |
| Type I and II endometrial cancers: have they different risk factors? VW Setiawan, HP Yang, MC Pike, SE McCann, H Yu, YB Xiang, A Wolk, ... Journal of Clinical Oncology 31 (20), 2607-2618, 2013 | 934 | 2013 |
| A large-scale study of the ultrawideband microwave dielectric properties of normal breast tissue obtained from reduction surgeries M Lazebnik, L McCartney, D Popovic, CB Watkins, MJ Lindstrom, J Harter, ... Physics in medicine & biology 52 (10), 2637, 2007 | 865 | 2007 |
| Comprehensive and integrated genomic characterization of adult soft tissue sarcomas AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ... Cell 171 (4), 950-965, 2017 | 840 | 2017 |
| Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non–small-cell lung cancer JD Bradley, C Hu, RR Komaki, GA Masters, GR Blumenschein, SE Schild, ... Journal of Clinical Oncology 38 (7), 706-714, 2020 | 444 | 2020 |
| Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). S Kopetz, SL McDonough, VK Morris, HJ Lenz, AM Magliocco, CE Atreya, ... Journal of Clinical Oncology 35 (4_suppl), 520-520, 2017 | 443* | 2017 |
| Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer EL Goode, MS Block, KR Kalli, RA Vierkant, W Chen, ZC Fogarty, ... JAMA oncology 3 (12), e173290-e173290, 2017 | 295 | 2017 |
| An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging S Drabycz, G Roldán, P De Robles, D Adler, JB McIntyre, AM Magliocco, ... Neuroimage 49 (2), 1398-1405, 2010 | 236 | 2010 |
| Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ... The Lancet Oncology 23 (1), 149-160, 2022 | 232 | 2022 |
| Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model WH Roa, S Azarmi, MHDK Al-Hallak, WH Finlay, AM Magliocco, ... Journal of Controlled Release 150 (1), 49-55, 2011 | 220 | 2011 |
| Identification of nine new susceptibility loci for endometrial cancer TA O’mara, DM Glubb, F Amant, D Annibali, K Ashton, J Attia, PL Auer, ... Nature communications 9 (1), 3166, 2018 | 217 | 2018 |
| Suppression of ING1 expression in sporadic breast cancer T Toyama, H Iwase, P Watson, H Muzik, E Saettler, A Magliocco, ... Oncogene 18 (37), 5187-5193, 1999 | 186 | 1999 |
| Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer EK Enwere, EN Kornaga, M Dean, TA Koulis, T Phan, M Kalantarian, ... Modern Pathology 30 (4), 577-586, 2017 | 169 | 2017 |
| Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme AE Sijben, JB McIntyre, GB Roldán, JC Easaw, E Yan, PA Forsyth, ... Journal of neuro-oncology 89, 97-103, 2008 | 164 | 2008 |
| Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer … D Yee, AM DeMichele, C Yau, C Isaacs, WF Symmans, KS Albain, ... JAMA oncology 6 (9), 1355-1362, 2020 | 149 | 2020 |
| Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 CT Williamson, E Kubota, JD Hamill, A Klimowicz, R Ye, H Muzik, M Dean, ... EMBO molecular medicine 4 (6), 515-527, 2012 | 146 | 2012 |
| A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors LM Kmet, LS Cook, AM Magliocco Cancer 97 (2), 389-404, 2003 | 140 | 2003 |
| Case–control study of the metabolic syndrome and metabolic risk factors for endometrial cancer CM Friedenreich, RK Biel, DCW Lau, I Csizmadi, KS Courneya, ... Cancer epidemiology, biomarkers & prevention 20 (11), 2384-2395, 2011 | 139 | 2011 |
| PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy JB McIntyre, JS Wu, PS Craighead, T Phan, M Köbel, SP Lees-Miller, ... Gynecologic oncology 128 (3), 409-414, 2013 | 132 | 2013 |
S P Lees-Miller, PhD, FRSCDepartment of Biochemistry & Molecular Biology, University of CalgaryDirección de correo verificada de ucalgary.ca
